Comparative Pharmacology
Head-to-head clinical analysis: EZALLOR SPRINKLE versus NEXIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EZALLOR SPRINKLE versus NEXIUM.
EZALLOR SPRINKLE vs NEXIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EZALLOR SPRINKLE (rosuvastatin) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. It increases hepatic LDL receptor expression, enhancing LDL clearance from plasma and reducing VLDL synthesis.
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme (proton pump) at the secretory surface of gastric parietal cells. It is the S-isomer of omeprazole and is a weak base that accumulates in the acidic environment of the parietal cell canaliculi, where it is converted to the active sulfenamide form that binds covalently to the proton pump, irreversibly inhibiting acid secretion.
40 mg orally once daily at bedtime; initial dose may be 20 mg. Dose range: 20-80 mg orally once daily.
20-40 mg orally once daily; IV: 20 mg once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 19 hours (range 13-20 hours) in healthy volunteers; half-life is prolonged in patients with hepatic impairment and severe renal impairment, necessitating dose adjustments.
Approximately 1–1.5 hours in extensive CYP2C19 metabolizers; in poor metabolizers, half-life can be prolonged to 2–3 hours. Clinically, the plasma half-life does not directly correlate with the duration of acid suppression due to prolonged binding to the proton pump.
Renal excretion accounts for approximately 88% of the administered dose (56% as unchanged rosuvastatin and 32% as metabolites); fecal excretion accounts for approximately 12%.
Primarily hepatic metabolism via CYP2C19 and CYP3A4; approximately 80% of metabolites excreted in urine, and the remainder in feces via biliary elimination. Less than 1% of unchanged drug is excreted in urine.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor